1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
    6.
    发明申请

    公开(公告)号:US20100081825A1

    公开(公告)日:2010-04-01

    申请号:US12444275

    申请日:2007-10-05

    IPC分类号: C07D211/58 C07D401/10

    摘要: Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

    摘要翻译: 公开了一种药物组合物,其包含式(I)表示的化合物或其药学上可接受的盐作为活性成分,其对黑色素浓缩激素受体具有拮抗作用。 由于其对MCH受体的拮抗活性,药物组合物可用于预防或治疗诸如抑郁症,焦虑症(例如广泛性焦虑症,创伤后应激障碍,恐慌症,强迫症, 社会焦虑障碍),注意力缺陷障碍,躁狂症,躁狂抑郁障碍,精神分裂症,情绪障碍,压力,睡眠障碍,发作,记忆障碍,认知障碍,痴呆,遗忘症,del妄,肥胖,进食障碍,食欲障碍, 糖尿病,心血管疾病,高血压,血脂异常,心肌梗死,运动障碍(如帕金森病,癫痫,惊厥,震颤),药物滥用和药物成瘾。

    1,3-dihydro-2H-indol-2-one derivative
    7.
    发明授权
    1,3-dihydro-2H-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US07528124B2

    公开(公告)日:2009-05-05

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中,R 1为卤素原子,C 1〜C 4烷基等,R 2为氢原子,卤素原子等) ,或R2为吲哚-2-酮的6-位,R 1和R 2连接在一起形成C 3〜C 6亚烷基,R 3为卤素原子,羟基等,R 4为氢原子 卤素原子,C 1〜C 4烷基等,或者R 4在苯基的3-位,R3和R4连接在一起形成亚甲二氧基,R5是氢原子或氟原子,R6是 乙基氨基,二甲基氨基等,R7为C1〜C4烷氧基,R8为C1〜C4烷氧基)或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。

    1,3-Dihydro-2h-indol-2-one derivative
    8.
    发明申请
    1,3-Dihydro-2h-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US20060276449A1

    公开(公告)日:2006-12-07

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中R 1是卤素原子,C 1至C 1烷基, 4个烷基等,R 2是氢原子,卤原子等,或R 2 2位在6位的 吲哚-2-酮和R 1和R 2连接在一起以形成C 6 -C 6亚烷基, 亚烷基,R 3是卤素原子,羟基等,R 4是氢原子,卤原子,C 1, / SUB→C 4烷基等,或R 4在苯基的3位和R 3和R 3 连接在一起形成亚甲二氧基,R 5是氢原子或氟原子,R 6是乙氨基,二甲基氨基 基团等,R 7是C 1-4烷氧基的C 1至C 8,并且R 8是 C 1至C 4烷氧基),或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。